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transplanted in ﬁrst CR otherwise all patients were
transplanted in relapsed/refractory setting. Patients were
grouped according to conditioning regimens.We aimed to
analyze the difference between the groups due to the total
number of febrile neutropenic days and hospitalization .We
also planned to compare the engraftment kinetics and side
effects between the groups.Table 1.
Patient demographics
BEAM(n:42) ICE(n:26)
Diagnosis
Hodgkin/Non Hodgkin lymphoma(n)
17/25 12/14 P:0.364
Median age (range) 43(17-66) 42(20-66) P:0.622
Gender:F/M 26/16 18/8 P: 0.417
Pretransplantation status
CR/PR/Refractory(n)
29/5/8 19/2/5 P:0.623
Pretransplantation RT(n) 9 5 P:0.542Results: The groupswere comparable according to diagnosis,
age, gender, pretransplantation status of disease and pre-
transplantation radiotherapy. We also showed no difference
between the groups according to infused CD344 cells, the
number of febrile neutropenic days,hospitalization and
neutrophile,platelet engraftment kinetics (Table 2). Nausea/
vomitting was slightly higher in the BEAM group but the
rates of mucositis were similar between the groups.Table 2
Transplant outcomes
BEAM ICE
Mean of transplanted CD34+ cells 6.4 3.3 5.7 2.8 P:0.364
Day Number of febrile neutropenia 3(1-12) 4(1-10) P:0.613
Day number of hospitalization 26(9-50) 24(12-67) P:0.846
No of neutrophile engraftment day 12(9-34) 11(8-21) P:0.354
No of platelet engraftment day 12(9-25) 12(8-21) p:0.500Conclusion: BEAM is one of the earliest described and
traditionally accepted conditioning regimens in AHSCT of
Hodgkin/Non Hodgkin lymphoma patients. Attempts of
several groups to change the drugs in BEAM regimens
showed no evidence of more antitumor effect. We showed
comparable transplantation outcomes between ICE and
BEAM regimens.
We conclude that ICE regimen can be preffered as
a conditioning regimen instead of BEAM regimen in selected
patient groups.129
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Peripheral blood has largely replaced bone marrow as the
source of stem cells for autologous transplantation. The
number of cells infused is a key determinant of hematopoi-
etic recovery after transplantation. Peripheral blood stem cell
(PBSC) yield can be affected by several factors such as donor
characteristics, disease status and prior treatment regimens.
We retrospectively analyzed the effect of body mass index
(BMI) on PBSC mobilization in 164 patients with plasma cell
dyscrasias. Patients were segregated based on BMI <25(Group I), 25-30 (Group II) and>30 (Group III). Since G-CSF is
dosed according to the actual body weight, patients with
higher BMI received higher total G-CSF dose (as well as
higher dose per kg ideal body weight) but the median stem
cell yield per kg IBW was similar in the 3 groups. (I¼ 2.2 x
103 cells/Kg, II¼ 2.1 x 103 cells/Kg and III¼ 2.3 x 103 cells/Kg;
P ¼ .76). We also evaluated the effect of BMI on the mobi-
lizing efﬁcacy of plerixafor. In our institution, patients
receive G-CSF at a dose of 10 mg/Kg daily subcutaneous
injections for three consecutive days. Patients with periph-
eral CD34+ cell count less than 10 x 106/L are considered
“poor mobilizers” and plerixafor at a dose of 0.24 mg/Kg SQ
daily is initiated starting on the fourth day for a maximum of
four days or until target number of cells are collected. The
fold increase in the median peripheral blood CD34+ count
after one dose of plerixafor was 8.1 (7.1  57.2/uL), 6.8 (7.2 
49.5/uL) and 3.6 (11  40.3 /uL) in BMI groups I, II and III,
respectively (p¼0.0675). Similarly, the administration of
plerixafor in addition to G-CSF did not give as much beneﬁt
in stem cell yield in higher BMI groups as seen in BMI < 25
group (p¼0.0063 in BMI<25 group and P ¼ .30 in BMI >30).
The reasons for these effects are unclear. Homing of the HPCs
in the adipose tissue (AT) may be a factor in higher BMI
individuals as the adipose tissue has similar biochemical and
molecular microenvironment as the bone marrow. The
pathophysiologic changes associated with obesity may alter
the pharmacokinetics and pharmacodynamics of subcuta-
neously administered drugs leading to their impaired efﬁ-
cacy. We believe these initial observations may have
important implications for clinical practice. Prospective
studies are needed to validate these ﬁndings and explore
whether these effects can be mitigated by intravenous route
of plerixafor administration.130
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Prior to introduction of Plerixafor, CXCR4 receptor antago-
nist, up to 30% of patients in need of autologous stem cell
transplant were unable to collect adequate numbers of
peripheral blood stem cells (PBSCs). Plerixafor is currently
approved for hematopoetic stem cell mobilization and
collection in combination with Filgrastim in patients with
Non-Hodgkin Lymphoma (NHL) and multiple myeloma
(MM) undergoing autologous stem cell transplantation. Due
to high costs associated with use of Plerixafor, the above
combination is usually reserved for patients who are at high
risk of failure or fail previous stem cell mobilization.
We have administed Plerixafor to 13 patients that failed to
achieve adequate peripheral blood pre CD34 counts after
undergoing stem cell mobilization utilizing the combination
of chemotherapy and Pegﬁlgrastim. We retrospectively
reviewed our data to evaluate efﬁcacy and safety of the above
combination.
Thirteen patients (25-69 years) with lymphoma (NHL
n¼ 4 HL n¼ 2) and MM (n¼7) underwent treatment with ICE
based chemotherapy or Cytoxan 3 gm/m2 followed by
